American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
    Journal Article

    Wang, X. V.; Hanson, C. A.; Tschumper, R. C.; Lesnick, C. E.; Braggio, E.; Paietta, E. M.; O'Brien, S.; Barrientos, J. C.; Leis, J. F.; Zhang, C. C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Lifelong TKI therapy: How to manage cardiovascular and other risks
    Review

    Mauro, M. J.
    Hematology-American Society of Hematology Education Program (2021)

    Fulltext@MSK | Save
  • How to choose first salvage therapy in Hodgkin lymphoma: Traditional chemotherapy vs novel agents
    Review

    Driessen, J.; Tonino, S. H.; Moskowitz, A. J.; Kersten, M. J.
    Hematology-American Society of Hematology Education Program (2021)

    Fulltext@MSK | Save
  • AL amyloidosis: Untangling new therapies
    Journal Article

    Bal, S.; Landau, H.
    Hematology-American Society of Hematology Education Program (2021)

    Fulltext@MSK | Save
  • A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
    Journal Article

    Réa, D.; Mauro, M. J.; Boquimpani, C.; Minami, Y.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, D. W.; Apperley, J. F.; Abdo, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • CNS involvement in AML at diagnosis is rare and does not affect response or survival: Data from 11 ECOG-ACRIN trials
    Journal Article

    Ganzel, C.; Lee, J. W.; Fernandez, H. F.; Paietta, E. M.; Luger, S. M.; Lazarus, H. M.; Cripe, L. D.; Douer, D.; Wiernik, P. H.; Rowe, J. M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: Is 4 Gy suitable for curable patients?
    Journal Article

    Imber, B. S.; Chau, K. W.; Lee, J.; Lee, J.; Casey, D. L.; Yang, J. C.; Wijentunga, N. A.; Shepherd, A.; Hajj, C.; Qi, S.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: A randomized, open-label phase 2 clinical trial
    Journal Article

    Cortes, J.; Apperley, J.; Lomaia, E.; Moiraghi, B.; Undurraga Sutton, M.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; Schiffer, C. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia
    Research Letter

    Rossoff, J.; Baggott, C.; Prabhu, S.; Pacenta, H.; Phillips, C. L.; Stefanski, H.; Talano, J. A.; Moskop, A.; Margossian, S. P.; Verneris, M. R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • COVID-19 in patients with CLL: Improved survival outcomes and update on management strategies
    Research Letter

    Roeker, L. E.; Eyre, T. A.; Thompson, M. C.; Lamanna, N.; Coltoff, A. R.; Davids, M. S.; Baker, P. O.; Leslie, L.; Rogers, K. A.; Allan, J. N.; more...
    Blood (2021)

    Fulltext@MSK | Save